BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Sep 05, 2008
 |  BC Extra  |  Clinical News

NeurAxon reports migraine data

NeurAxon (Waltham, Mass.) said NXN-188 missed the primary endpoint in a double-blind Phase II trial in 60 patients with migraine. The small molecule neuronal nitric oxide (NO) synthase inhibitor and serotonin...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >